Gaucher disease – a comprehensive review of clinical characteristics, diagnostic algorythms and current therapies
DOI:
https://doi.org/10.12775/QS.2024.26.54859Keywords
lysosomal storage disease, Anemia, diagnostic algorithms, splenomegaly, enzyme replacement therapy, genetic diseasesAbstract
Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder caused by mutations in the GBA1 gene, which encodes the enzyme glucocerebrosidase. This enzyme is crucial for breaking down glucocerebrosides, and its deficiency leads to their accumulation in the monocyte-macrophage system, forming Gaucher cells. These cells build up in the bone marrow, spleen, and liver, causing various clinical manifestations. GD is classified into three types based on clinical features and progression: GD1 (non-neuronopathic), GD2 (acute neuronopathic), and GD3 (subacute neuronopathic).
GD1, the most common form, usually presents with splenomegaly, hepatomegaly, anemia, thrombocytopenia, and skeletal symptoms and has a relatively mild course. GD2 is marked by severe neurological involvement, with a poor prognosis and a maximum survival of three years. GD3 features a mix of visceral, hematological, neurological, and skeletal symptoms, with a variable prognosis depending on the subtype.
Epidemiologically, GD is rare in the general population but more common among Ashkenazi Jews, who have a higher carrier frequency and prevalence. The genetic basis of GD is well-documented, with several mutations associated with different disease severities and outcomes. Diagnostic procedures include a comprehensive medical history, imaging studies, and biochemical and genetic tests to confirm reduced glucocerebrosidase activity and identify GBA1 mutations.
Current treatments focus on enzyme replacement therapy (ERT) and substrate reduction therapy (SRT), with supportive care for specific symptoms. ERT is the primary treatment for all children with GD1 and GD3 and for adults who meet certain criteria, while SRT is an alternative for milder forms of GD1. Despite advances in treatment, managing GD remains complex, requiring a multidisciplinary approach to address the diverse clinical manifestations and improve patient outcomes.
References
Aerts, J. M. F. G., Kallemeijn, W. W., Wegdam, W., Joao Ferraz, M., van Breemen, M. J., Dekker, N., Kramer, G., Poorthuis, B. J., Groener, J. E. M., Cox-Brinkman, J., Rom-bach, S. M., Hollak, C. E. M., Linthorst, G. E., Witte, M. D., Gold, H., van der Marel, G. A., Overkleeft, H. S., & Boot, R. G. (2011). Biomarkers in the diagnosis of lysosomal sto-rage disorders: proteins, lipids, and inhibodies. Journal of Inherited Metabolic Disease, 34(3), 605. https://doi.org/10.1007/S10545-011-9308-6
Arends, M., van Dussen, L., Biegstraaten, M., & Hollak, C. E. M. (2013). Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature. British Journal of Haematology, 161(6), 832–842. https://doi.org/10.1111/BJH.12335
Barrett, M. J., Giraldo, P., Capablo, J. L., Alfonso, P., Irun, P., Garcia-Rodriguez, B., Po-covi, M., & Pastores, G. M. (2013). Greater risk of parkinsonism associated with non-N370S GBA1 mutations. Journal of Inherited Metabolic Disease, 36(3), 575–580. https://doi.org/10.1007/S10545-012-9527-5
Becker, J. G., Pastores, G. M., di Rocco, A., Ferraris, M., Graber, J. J., & Sathe, S. (2013). Parkinson’s disease in patients and obligate carriers of Gaucher disease. Parkin-sonism & Related Disorders, 19(1), 129–131. https://doi.org/10.1016/J.PARKRELDIS.2012.06.023
Bennett, L. L., & Mohan, D. (2013). Gaucher disease and its treatment options. The An-nals of Pharmacotherapy, 47(9), 1182–1193. https://doi.org/10.1177/1060028013500469
Concolino, D., Mussari, A., Filocamo, M., & Strisciuglio, P. (2003). Rare compound he-terozygosity for IVS2 +1G>A and R170P in an Italian patient with Gaucher disease type 1. Clinical Genetics, 64(3), 261–262. https://doi.org/10.1034/J.1399-0004.2003.00129.X
Cox, T. M., Aerts, J. M. F. G., Belmatoug, N., Cappellini, M. D., Dahl, S., Goldblatt, J., Grabowski, G. A., Hollak, C. E. M., Hwu, P., Maas, M., Martins, A. M., Mistry, P. K., Pa-stores, G. M., Tylki-Szymanska, A., Yee, J., & Weinreb, N. (2008). Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bi-sphosphonate therapy, use of biomarkers and bone disease monitoring. Journal of Inheri-ted Metabolic Disease, 31(3), 319–336. https://doi.org/10.1007/S10545-008-0779-Z
Deegan, P. B., Pavlova, E., Tindall, J., Stein, P. E., Bearcroft, P., Mehta, A., Hughes, D., Wraith, J. E., & Cox, T. M. (2011). Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy. Medicine, 90(1), 52–60. https://doi.org/10.1097/MD.0B013E3182057BE4
di Rocco, M., Andria, G., Deodato, F., Giona, F., Micalizzi, C., & Pession, A. (2014). Early diagnosis of Gaucher disease in pediatric patients: proposal for a diagnostic algo-rithm. Pediatric Blood & Cancer, 61(11), 1905–1909. https://doi.org/10.1002/PBC.25165
Diaz, G. A., Gelb, B. D., Risch, N., Nygaard, T. G., Frisch, A., Cohen, I. J., Sa Miranda, C., Amaral, O., Maire, I., Poenaru, L., Caillaud, C., Weizberg, M., Mistry, P., & Desnick, R. J. (2000). Gaucher disease: the origins of the Ashkenazi Jewish N370S and 84GG acid beta-glucosidase mutations. American Journal of Human Genetics, 66(6), 1821. https://doi.org/10.1086/302946
Park JK, Koprivica V, Andrews DQ, Madike V, Tayebi N, Stone DL, Sidransky E. Gluco-cerebrosidase mutations among African-American patients with type 1 Gaucher disease. Am J Med Genet. 2001 Mar 1;99(2):147-51. doi: 10.1002/1096-8628(2001)9999:9999<::aid-ajmg1144>3.0.co;2-1. PMID: 11241475.
Goker-Alpan, O. (2011). Therapeutic approaches to bone pathology in Gaucher disease: past, present and future. Molecular Genetics and Metabolism, 104(4), 438–447. https://doi.org/10.1016/J.YMGME.2011.08.004
Grabowski, G. A. (2006). Delivery of lysosomal enzymes for therapeutic use: glucocere-brosidase as an example. Expert Opinion on Drug Delivery, 3(6), 771–782. https://doi.org/10.1517/17425247.3.6.771
Grabowski, G. A. (2008). Phenotype, diagnosis, and treatment of Gaucher’s disease. Lan-cet (London, England), 372(9645), 1263–1271. https://doi.org/10.1016/S0140-6736(08)61522-6
Grabowski, G. A., Andria, G., Baldellou, A., Campbell, P. E., Charrow, J., Cohen, I. J., Harris, C. M., Kaplan, P., Mengel, E., Pocovi, M., & Vellodi, A. (2004). Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus sta-tements. European Journal of Pediatrics, 163(2), 58–66. https://doi.org/10.1007/S00431-003-1362-0
Grabowski, G. A., Zimran, A., & Ida, H. (2015). Gaucher disease types 1 and 3: Phenoty-pic characterization of large populations from the ICGG Gaucher Registry. American Jo-urnal of Hematology, 90 Suppl 1(S1), S12–S18. https://doi.org/10.1002/AJH.24063
Grabowski, G., Barnes, & Burrow. (2011). Prevalence and management of Gaucher dise-ase. Pediatric Health, Medicine and Therapeutics, 59. https://doi.org/10.2147/PHMT.S12499
Hruska, K. S., LaMarca, M. E., Scott, C. R., & Sidransky, E. (2008). Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Human Mutation, 29(5), 567–583. https://doi.org/10.1002/HUMU.20676
Ida, H., Iwasawa, K., Kawame, H., Rennert, O. M., Maekawa, K., & Eto, Y. (1995). Cha-racteristics of gene mutations among 32 unrelated Japanese Gaucher disease patients: ab-sence of the common Jewish 84GG and 1226G mutations. Human Genetics, 95(6), 717–720. https://doi.org/10.1007/BF00209497
Kaplan, P., Baris, H., de Meirleir, L., di Rocco, M., El-Beshlawy, A., Huemer, M., Mar-tins, A. M., Nascu, I., Rohrbach, M., Steinbach, L., & Cohen, I. J. (2013). Revised re-commendations for the management of Gaucher disease in children. European Journal of Pediatrics, 172(4), 447–458. https://doi.org/10.1007/S00431-012-1771-Z
Langeveld, M., Fost, M. de, Aerts, J. M. F. G., Sauerwein, H. P., & Hollak, C. E. M. (2008). Overweight, insulin resistance and type II diabetes in type I Gaucher disease pa-tients in relation to enzyme replacement therapy. Blood Cells, Molecules & Diseases, 40(3), 428–432. https://doi.org/10.1016/J.BCMD.2007.09.002
LeBowitz, J. H. (2005). A breach in the blood-brain barrier. Proceedings of the National Academy of Sciences of the United States of America, 102(41), 14485. https://doi.org/10.1073/PNAS.0507523102
Maas, M., Poll, L. W., & Terk, M. R. (2002). Imaging and quantifying skeletal involve-ment in Gaucher disease. The British Journal of Radiology, 75 Suppl 1(SUPPL. 1). https://doi.org/10.1259/BJR.75.SUPPL_1.750013
Machaczka, M., Björkvall, C. K., Wieremiejczyk, J., Arce, M. P., Myhr-Eriksson, K., Klimkowska, M., Hägglund, H., & Svenningsson, P. (2015). Impact of imiglucerase sup-ply shortage on clinical and laboratory parameters in Norrbottnian patients with Gaucher disease type 3. Archivum Immunologiae et Therapiae Experimentalis, 63(1), 65–71. https://doi.org/10.1007/S00005-014-0308-8
MacHaczka, M., Hast, R., Dahlman, I., Lerner, R., Klimkowska, M., Engvall, M., & Hgglund, H. (2012). Substrate reduction therapy with miglustat for type 1 Gaucher disea-se: A retrospective analysis from a single institution. Upsala Journal of Medical Scien-ces, 117(1), 28. https://doi.org/10.3109/03009734.2011.64160
Machaczka, M., Lerner, R., Klimkowska, M., & Hägglund, H. (2009). Treatment of mul-tiple myeloma in patients with Gaucher disease. American Journal of Hematology, 84(10), 694–696. https://doi.org/10.1002/AJH.21492
Machaczka, M., Paucar, M., Björkvall, C. K., Smith, N. J. C., Cox, T. M., Forsgren, L., & Svenningsson, P. (2018). Novel hyperkinetic dystonia-like manifestation and neurologi-cal disease course of Swedish Gaucher patients. Blood Cells, Molecules & Diseases, 68, 86–92. https://doi.org/10.1016/J.BCMD.2016.10.011
Mistry, P. (2006). Phenotype variations in Gaucher disease. La Revue de Médecine Inter-ne, 27, S3–S6. https://doi.org/10.1016/S0248-8663(06)80002-0
Mistry, P. K., Cappellini, M. D., Lukina, E., Özsan, H., Mach Pascual, S., Rosenbaum, H., Helena Solano, M., Spigelman, Z., Villarrubia, J., Watman, N. P., & Massenkeil, G. (2011). A reappraisal of Gaucher disease-diagnosis and disease management algorithms. American Journal of Hematology, 86(1), 110–115. https://doi.org/10.1002/AJH.21888
Mistry, P. K., Lukina, E., Turkia, H. ben, Amato, D., Baris, H., Dasouki, M., Ghosn, M., Mehta, A., Packman, S., Pastores, G., Petakov, M., Assouline, S., Balwani, M., Danda, S., Hadjiev, E., Ortega, A., Shankar, S., Solano, M. H., Ross, L., … Peterschmitt, M. J. (2015). Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial. JAMA, 313(7), 695–706. https://doi.org/10.1001/JAMA.2015.459
Mistry, P. K., Taddei, T., vom Dahl, S., & Rosenbloom, B. E. (2013). Gaucher Disease and Malignancy: A Model for Cancer Pathogenesis in an Inborn Error of Metabolism. Critical Reviews in Oncogenesis, 18(3), 235. https://doi.org/10.1615/CRITREVONCOG.2013006145
Park, J. K., Orvisky, E., Tayebi, N., Kaneski, C., Lamarca, M. E., Stubblefield, B. K., Martin, B. M., Schiffmann, R., & Sidransky, E. (2003). Myoclonic epilepsy in Gaucher disease: genotype-phenotype insights from a rare patient subgroup. Pediatric Research, 53(3), 387–395. https://doi.org/10.1203/01.PDR.0000049515.79882.94
Rolfs, A., Giese, A. K., Grittner, U., Mascher, D., Elstein, D., Zimran, A., Böttcher, T., Lukas, J., Hübner, R., Gölnitz, U., Röhle, A., Dudesek, A., Meyer, W., Wittstock, M., & Mascher, H. (2013). Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Cauca-sian cohort of Gaucher disease patients. PloS One, 8(11). https://doi.org/10.1371/JOURNAL.PONE.0079732
Rosenbloom, B. E., & Weinreb, N. J. (2013). Gaucher disease: a comprehensive review. Critical Reviews in Oncogenesis, 18(3), 163–175. https://doi.org/10.1615/CRITREVONCOG.2013006060
Scott, S. A., Edelmann, L., Liu, L., Luo, M., Desnick, R. J., & Kornreich, R. (2010). Experience with Carrier Screening and Prenatal Diagnosis for Sixteen Ashkenazi Jewish Genetic Diseases. Human Mutation, 31(11), 1240. https://doi.org/10.1002/HUMU.21327
Sims, K. B., Pastores, G. M., Weinreb, N. J., Barranger, J., Rosenbloom, B. E., Packman, S., Kaplan, G., Mankin, H., Xavier, R., Angell, J., Fitzpatrick, M. A., & Rosenthal, D. (2008). Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clinical Genetics, 73(5), 430. https://doi.org/10.1111/J.1399-0004.2008.00978.X
Stirnemann, J. Ô., Belmatoug, N., Camou, F., Serratrice, C., Froissart, R., Caillaud, C., Levade, T., Astudillo, L., Serratrice, J., Brassier, A., Rose, C., de Villemeur, T. B., & Berger, M. G. (2017). A Review of Gaucher Disease Pathophysiology, Clinical Presenta-tion and Treatments. International Journal of Molecular Sciences, 18(2). https://doi.org/10.3390/IJMS18020441
Weinreb, N. J., Aggio, M. C., Andersson, H. C., Andria, G., Charrow, J., Clarke, J. T. R., Erikson, A., Giraldo, P., Goldblatt, J., Hollak, C., Ida, H., Kaplan, P., Kolodny, E. H., Mi-stry, P., Pastores, G. M., Pires, R., Prakesh-Cheng, A., Rosenbloom, B. E., Scott, C. R., … Zimran, A. (2004). Gaucher disease type 1: Revised recommendations on evaluations and monitoring for adult patients. Seminars in Hematology, 41(SUPPL. 5), 15–22. https://doi.org/10.1053/j.seminhematol.2004.07.010
Weinreb, N. J., Barranger, J., Packman, S., Prakash-Cheng, A., Rosenbloom, B., Sims, K., Angell, J., Skrinar, A., & Pastores, G. M. (2007). Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease. Clinical Gene-tics, 71(6), 576–588. https://doi.org/10.1111/J.1399-0004.2007.00811.X
Weinreb, N. J., Charrow, J., Andersson, H. C., Kaplan, P., Kolodny, E. H., Mistry, P., Pa-stores, G., Rosenbloom, B. E., Scott, C. R., Wappner, R. S., & Zimran, A. (2002). Effec-tiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: A report from the Gaucher Registry. American Journal of Medicine, 113(2), 112–119. https://doi.org/10.1016/S0002-9343(02)01150-6
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Alicja Kotula, Natalia Kucy, Adrianna Czachor, Paula Kula, Mateusz Haber, Olga Grelewicz, Elwira Servaas, Adam Juśkiewicz, Alicja Pilcicka
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 65
Number of citations: 0
